LITIGATION OR DISPUTES. 22. The Agent will provide prompt notice in writing to AMS of any claims, demands, disputes or potential legal actions for which the Agent may be, or become, liable to under the terms of this Agreement.
LITIGATION OR DISPUTES. Except as set forth on Schedule 4.1(h), there is no claim, action, suit, demand, citation, grievance, subpoena, inquiry, proceeding, investigation, or arbitration relating to the Product, the Purchased Assets or the Adderall Business pending or, to Shire’s knowledge, threatened against Shire or any of its Affiliates by or before any Regulatory Authority, federal, state, or other governmental court, department, commission, or board (whether domestic or foreign). Except as set forth on Schedule 4.1(h), there is not currently outstanding against Shire or any of its Affiliates any judgment, decree, injunction, rule or order of any Regulatory Authority or Governmental Authority relating to the Purchased Assets or the Adderall Business.
LITIGATION OR DISPUTES. Except as disclosed in Schedule 4.01(f) attached hereto, there is no claim, outstanding commitment to any governmental regulatory agency, action, suit, proceeding, investigation, or arbitration pending or, to GW's knowledge, threatened against GW relating to the Assets, and GW is not in violation of or in default with respect to any applicable law, rule, regulation, judgment, order, writ, injunction, award, or decree of any arbitrator, court, or administrative body, the result of any of which, either individually or cumulatively, would have a materially adverse effect on the Assets in the Territory or GW's compliance with and performance under the terms of this Agreement or the Collateral Agreements.
LITIGATION OR DISPUTES. Except as disclosed in SCHEDULE 4.01(f) attached hereto, there is no claim, outstanding commitment to any governmental regulatory agency, action, suit, proceeding, investigation, or arbitration pending or, to KING's knowledge, threatened against KING relating to the Assets and, to KING's knowledge, no event has occurred nor does any condition exist on the basis of which any such proceeding would reasonably be expected to be instituted with any substantial chance of recovery, and KING is not in violation of or in default with respect to any applicable law, rule, regulation, judgment, order, writ, injunction, award, or decree of any arbitrator, court, or administrative body, the result of any of which, either individually or cumulatively, would have a materially adverse effect on the Assets in the Territory or KING's compliance with and performance under the terms of this Agreement or the Collateral Agreements.
LITIGATION OR DISPUTES. There is no claim, outstanding commitment to any governmental regulatory agency, action, suit, proceeding, investigation, or arbitration pending or, to Seller's knowledge, threatened against Seller relating to the Assets, and Seller is not in violation of or in default with respect to any applicable law, rule, regulation, judgment, order, writ, injunction, award, or decree of any arbitrator, court, or administrative body, the result of any of which, either individually or cumulatively, would have a materially adverse effect on the Assets or Seller's compliance with and performance under the terms of this Agreement.
LITIGATION OR DISPUTES. Except as disclosed in EXHIBIT C attached hereto, Novavax represents and warrants that there is no actual or potential claim, outstanding commitment to any governmental regulatory agency, action, suit, proceeding, investigation or arbitration, either pending, known to Novavax or threatened against Novavax, which relates to or concerns the Adjuvants, the Novasome(R) delivery system, the Novasome(R) delivery system trademark, the Patent Rights, the Novavax Know-How, the Novavax Improvements and/or the Novavax IP. Novavax further represents and warrants that it is not in violation of or in default with respect to any applicable law, rule, regulation, judgment, order, writ, injunction, award, or decree of any arbitrator, court, or administrative body, the result of any of which, either individually or cumulatively, would have a materially adverse effect on the Adjuvants, the Novasome(R) delivery system, the Patent Rights, the Novavax Know-How, the Novavax Improvements or the Novavax IP in the Territory or Novavax's compliance with and performance under the terms of this License and Supply Agreement.
LITIGATION OR DISPUTES. Except as disclosed in Schedule 4.01(f) attached hereto, there is no claim, outstanding commitment to any governmental regulatory agency, action, suit,
LITIGATION OR DISPUTES. There is no claim, outstanding commitment to any governmental regulatory agency, action, suit, proceeding, investigation, or arbitration pending or, to NOVAVAX’s knowledge, threatened against NOVAVAX or FIELDING relating to the Assets and, to NOVAVAX’s knowledge, no event has occurred nor does any condition exist on the basis of which any such proceeding would reasonably be expected to be instituted with any substantial chance of recovery, and neither NOVAVAX nor FIELDING is in violation of or in default with respect to any applicable law, rule, regulation, judgment, order, writ, injunction, award, or decree of any arbitrator, court, or administrative body, the result of any of which, either individually or cumulatively, would have a materially adverse effect on the Assets or NOVAVAX’s or FIELDING’s compliance with and performance under the terms of this Agreement or the Transaction Documents to which it is a party.
LITIGATION OR DISPUTES. To the knowledge of Thera, there is no claim, action, suit, proceeding, hearing, enforcement, investigation, or arbitration pending or threatened against Thera relating to the Product.
LITIGATION OR DISPUTES. Except as set forth on Schedule 4.1(h), there is no claim, action, suit, proceeding, or arbitration pending or, to Seller’s knowledge, threatened against Seller or any of its Affiliates relating to the Products or the Product Assets. Except as set forth on Schedule 4.1(h), there is not currently outstanding against Seller or any of its Affiliates any judgment, decree, injunction, rule or order of any Regulatory Authority or Governmental Authority relating to the Products or the Product Assets.
